<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978454</url>
  </required_header>
  <id_info>
    <org_study_id>20-0005</org_study_id>
    <secondary_id>75N93019C00054</secondary_id>
    <nct_id>NCT04978454</nct_id>
  </id_info>
  <brief_title>Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain</brief_title>
  <official_title>A Multicenter, Blinded, Randomized, Placebo-Controlled, Dose-Ranging Influenza Challenge Study in Healthy Adult Volunteers to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2), Clade 3C3a) Influenza Challenge Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, dose-ranging influenza challenge study in healthy adult volunteers to&#xD;
      determine the optimal infection dose and safety of a recombinant H3N2 (A/Texas/&#xD;
      A/Texas/71/2017 (H3N2, clade 3C3a) influenza strain. The goal of this study is to find a&#xD;
      challenge virus dose that is safe and can achieve a symptomatic influenza Attack Rate (AR)&#xD;
      that will be sufficiently high for utilization in future vaccine or intervention studies. The&#xD;
      optimal dose of the three considered is broadly defined as the minimum challenge virus dose&#xD;
      that elicits the highest AR without meeting safety-stopping criteria. Additionally, viral&#xD;
      recovery, clinical symptoms, and immune responses over the post-challenge period will be&#xD;
      described by challenge dose group. This study will last for up to 1 year depending upon the&#xD;
      number of challenge cohorts enrolled given the adaptive dose-escalation design. The&#xD;
      populations are healthy males and non-pregnant, non-breastfeeding females aged = 18 and &lt; 46&#xD;
      years of age with a serum HAI antibody titer of &lt;/=1:40 against influenza A/Texas/71/2017&#xD;
      (H3N2), clade 3C3a.The study will enroll and challenge up to 106 (plus 8 shams) healthy adult&#xD;
      volunteers with the H3N2 (A/Texas/71/2017 (H3N2), clade 3C3a) influenza virus challenge&#xD;
      strain. The primary objectives are: 1) To determine the optimal infectious dose1 of a&#xD;
      recombinant influenza virus (A/Texas/71/2017 (H3N2), clade 3C3a) to be used as a clinical&#xD;
      challenge strain in future vaccine efficacy or intervention studies as assessed by viral&#xD;
      shedding and clinical symptoms. 2) To describe viral detection by quantitative and&#xD;
      qualitative Reverse Transcription - Polymerase Chain Reaction (RT-PCR) from study subjects at&#xD;
      baseline and post-challenge. 3) To document clinical symptoms from self-reported surveys and&#xD;
      standardized symptom scales at baseline and post-challenge.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, dose-ranging influenza challenge study in healthy adult volunteers to&#xD;
      determine the optimal infection dose and safety of a recombinant H3N2 (A/Texas/&#xD;
      A/Texas/71/2017 (H3N2, clade 3C3a) influenza strain. The goal of this study is to find a&#xD;
      challenge virus dose that is safe and can achieve a symptomatic influenza Attack Rate (AR)&#xD;
      that will be sufficiently high for utilization in future vaccine or intervention studies. The&#xD;
      optimal dose of the three considered is broadly defined as the minimum challenge virus dose&#xD;
      that elicits the highest AR without meeting safety-stopping criteria. Additionally, viral&#xD;
      recovery, clinical symptoms, and immune responses over the post-challenge period will be&#xD;
      described by challenge dose group. This study will last for up to 1 year depending upon the&#xD;
      number of challenge cohorts enrolled given the adaptive dose-escalation design. The&#xD;
      populations are healthy males and non-pregnant, non-breastfeeding females aged = 18 and &lt; 46&#xD;
      years of age with a serum HAI antibody titer of &lt;/=1:40 against influenza A/Texas/71/2017&#xD;
      (H3N2), clade 3C3a.The study will enroll and challenge up to 106 (plus 8 shams) healthy adult&#xD;
      volunteers with the H3N2 (A/Texas/71/2017 (H3N2), clade 3C3a) influenza virus challenge&#xD;
      strain. Subjects will be pre-screened for study inclusion to have serological HAI antibody&#xD;
      titers of &lt;/=1:40 against the clinical challenge strain. Eligible participants will be&#xD;
      enrolled sequentially into dosing cohorts and will be randomly assigned to receive a single&#xD;
      dose of either placebo (sham inoculum) or a virus dose between 104 to 106 Median Issue&#xD;
      Culture Infectious Dose (TCID50) (in an allocation of 1:12 to 1:17). Dose titration will be&#xD;
      conducted under an adaptive escalation schedule whereby dosing will start at the lowest dose&#xD;
      104 TCID50 and only escalate to the next dose if a pre-determined infection and symptomatic&#xD;
      attack rate are not met and the dose is determined to be safe and no pre-defined halting rule&#xD;
      is met. The attack rate (AR), defined as the percentage of subjects meeting shedding and&#xD;
      symptom criteria for symptomatic influenza virus infection (see clinical case definition&#xD;
      below), will be determined for each challenge dose group in order to identify the optimal&#xD;
      infectious dose (55%-80% AR). This adaptive, dose-ranging approach allows adjustments to&#xD;
      challenge dose group size and escalation dose schedule to be informed by the AR and safety&#xD;
      results. The primary objectives are: 1) To determine the optimal infectious dose1 of a&#xD;
      recombinant influenza virus (A/Texas/71/2017 (H3N2), clade 3C3a) to be used as a clinical&#xD;
      challenge strain in future vaccine efficacy or intervention studies as assessed by viral&#xD;
      shedding and clinical symptoms. 2) To describe viral detection by quantitative and&#xD;
      qualitative Reverse Transcription - Polymerase Chain Reaction (RT-PCR) from study subjects at&#xD;
      baseline and post-challenge. 3) To document clinical symptoms from self-reported surveys and&#xD;
      standardized symptom scales at baseline and post-challenge. The secondary objectives are: 1)&#xD;
      To assess the safety profile of a live recombinant influenza strain (A/Texas/71/2017 (H3N2),&#xD;
      clade 3C3a) following challenge in healthy adult volunteers. 2) To describe the host serum&#xD;
      antibody responses at baseline and post-challenge. 3) To describe&#xD;
      anti-Hemagglutination(HA)-stalk antibody titer at baseline and post-challenge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">April 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in computed total symptom score</measure>
    <time_frame>Day 1 through Day 15</time_frame>
    <description>Computed total symptom score by modified Jackson score from self-reported surveys</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in magnitude of virus shedding</measure>
    <time_frame>Day 2 to Day 8</time_frame>
    <description>Defined as the peak viral load in nasopharyngeal (NP) swab(s) challenge by quantitative Transcription - Polymerase Chain Reaction (RT-PCR) post-challenge in each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of viral shedding</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Defined as the number of days from first positive Reverse Transcription - Polymerase Chain Reaction (RT-PCR) to last positive RT-PCR where virus is detected in NP swab(s) by quantitative and qualitative RT-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with detectable shedding over any 2 days</measure>
    <time_frame>Day 2 to Day 8</time_frame>
    <description>Assessed by viral shedding in nasopharyngeal (NP) swab(s) by Reverse Transcription - Polymerase Chain Reaction (RT-PCR) and clinical symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with detected viral shedding each day</measure>
    <time_frame>Day 2 to Day 8</time_frame>
    <description>Assessed by viral shedding in nasopharyngeal (NP) swab(s) using qualitative and quantitative Reverse Transcription - Polymerase Chain Reaction (RT-PCR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with total symptom scores that define symptomatic or asymptomatic categories based on modified Jackson score</measure>
    <time_frame>Day 1 through Day 15</time_frame>
    <description>Based on modified Jackson score for each subject from self-reported surveys</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Geometric Mean Titers (GMT) of Hemagglutinin (HA)-stalk specific response</measure>
    <time_frame>Day -1 to Day 29</time_frame>
    <description>Hemagglutinin (HA) group 2 stem domains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Geometric Mean Titers (GMT) of serum antibodies</measure>
    <time_frame>Day -1 to Day 29</time_frame>
    <description>Serum antibodies: Hemagglutination inhibition (HAI) antibody, Neuraminidase inhibition (NAI) antibody, Microneutralization (MN) antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of Hemagglutinin (HA)-stalk specific response</measure>
    <time_frame>Day 8 to Day 29</time_frame>
    <description>Hemagglutinin (HA) group 2 stem domains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of serum antibodies</measure>
    <time_frame>Day 8 to Day 29</time_frame>
    <description>Serum antibodies: Hemagglutination inhibition (HAI) antibody, Neuraminidase inhibition (NAI) antibody, Microneutralization (MN) antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AE)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAE)</measure>
    <time_frame>Day 1 through Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects reporting any adverse events (AE)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects reporting any serious adverse events (SAE)</measure>
    <time_frame>Day 1 through Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with serological conversion of Hemagglutinin (HA)-stalk specific serum antibody</measure>
    <time_frame>Day -1 to Day 29</time_frame>
    <description>Serological conversion defined as a minimum 4-fold rise in post-challenge Hemagglutinin (HA)-stalk specific serum antibody response to HA group 2 stem domains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with serological conversion of serum antibodies</measure>
    <time_frame>Day -1 to Day 29</time_frame>
    <description>Serological conversion defined as a minimum 4-fold rise in post-challenge serum antibodies (Hemagglutination inhibition (HAI) antibody, Neuraminidase inhibition (NAI) antibody, Microneutralization (MN) antibody)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^4 TCID50of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (500 uL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (500 uL per nostril) (n=1) administered intranasally on Day 1. If 80% or more subjects in Cohort 1A meet the case definition for influenza, proceed to Cohort 1B. If fewer than 80% of subjects meet the case definition for influenza in Cohort 1A, the dose will escalate to include Cohort 2A. N = 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^4 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (500 uL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (500 uL per nostril) (n=1) administered intranasally on Day 1. If 80% or more subjects in Cohort 1A and 1B meet the case definition for influenza, proceed to Cohort 1C. Cumulatively, if fewer than 80% of subjects in Cohorts 1A and 1B meet the case definition for influenza, the dose will escalate to include Cohort 2A. N = 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^4 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (500 uL per nostril) influenza virus (n=12) and sham sucrose phosphate glutamate (SPG) inoculum 1.0 mL (500 uL per nostril) (n=1) administered intranasally on Day 1. If 80% or more of the subjects in Cohorts 1A, 1B, and 1C combined meet the case definition for influenza then the optimal dose of 104 TCID50 will be selected. Cumulatively, if fewer than 80% of subjects in Cohorts 1A, 1B, and 1C meet the case definition for influenza the dose will escalate to include Cohort 2A. N = 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (500 uL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (500 uL per nostril) (n=1) administered intranasally on Day 1. If 70% or more subjects in Cohort 2A meet the case definition for influenza, proceed to Cohort 1B. If fewer than 70% of subjects meet the case definition for influenza in Cohort 2A, the dose will escalate to include Cohort 3A. N = 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (500 uL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (500 uL per nostril) (n=1) administered intranasally on Day 1.If 70% or more subjects in Cohort 2A and 2B meet the case definition for influenza, proceed to Cohort 2C. Cumulatively, if fewer than 70% of subjects in Cohorts 2A and 2B meet the case definition for influenza, the dose will escalate to include Cohort 3A N = 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^5 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (500 uL per nostril) influenza virus (n=12) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (500 uL per nostril) (n=1) administered intranasally on Day 1. If 70% or more of the subjects in Cohorts 2A, 2B, and 2C combined meet the case definition for influenza then the optimal dose of 10^4 TCID50 will be selected. Cumulatively, if fewer than 70% of subjects in Cohorts 2A, 2B, and 2C meet the case definition for influenza the dose will escalate to include Cohort 3A. N = 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^6 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (500 uL per nostril) influenza virus (n=17) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (500 uL per nostril) (n=1) administered intranasally on Day 1. If no safety threshold is met (halting conditions) proceed to Cohort 3B. N = 18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^6 TCID50 of recombinant H3N2 (A/Texas/71/2017, clade 3C3a) 1.0 mL (500 uL per nostril) influenza virus (n=17) and Sham Sucrose phosphate glutamate (SPG) inoculum 1.0 mL (500 uL per nostril) (n=1) administered intranasally on Day 1. N = 18</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza RG-A/Texas/71/2017 (H3N2) Challenge</intervention_name>
    <description>RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 500 ?L per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 1C</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_label>Cohort 2C</arm_group_label>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_label>Cohort 3B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sucrose phosphate glutamate (SPG) inoculum</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 1C</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_label>Cohort 2C</arm_group_label>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_label>Cohort 3B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent prior to initiation of any study procedure&#xD;
&#xD;
          2. Are able to understand and comply with planned study procedures and be available for&#xD;
             all study visits&#xD;
&#xD;
          3. Agree to remain an inpatient for at least 7 days after challenge AND until they have&#xD;
             no viral shedding*, determined by qualitative Reverse Transcription - Polymerase Chain&#xD;
             Reaction (RT-PCR) beginning on Day 7 post-challenge&#xD;
&#xD;
             *No viral shedding is defined as two negative RT-PCR tests 12 or more hours apart&#xD;
&#xD;
          4. Healthy* males and non-pregnant, non-breastfeeding females aged &gt; / = 18 and &lt; 46&#xD;
             years of age at enrollment&#xD;
&#xD;
             *Healthy is defined in inclusion criteria #11. NOTE: Female subjects of childbearing&#xD;
             potential must have a negative serum pregnancy test at screening, a negative urine&#xD;
             pregnancy test upon admission to the inpatient challenge unit AND a negative pregnancy&#xD;
             test before any Chest x-ray (CXR) (if &gt; / = 7 days have passed since a serum pregnancy&#xD;
             test).&#xD;
&#xD;
          5. Women of childbearing potential* must agree to use or have practiced true abstinence**&#xD;
             or use at least one acceptable primary form of contraception* for at least 30 days&#xD;
             prior to challenge&#xD;
&#xD;
               -  Not of child bearing potential - post-menopausal females (defined as having a&#xD;
                  history of amenorrhea for at least one year) or a documented status as being&#xD;
                  surgically sterile (hysterectomy, bilateral oophorectomy, tubal&#xD;
                  ligation/salpingectomy, or Essure(R) placement with history of documented&#xD;
                  radiological confirmation test at least 90 days after the procedure).&#xD;
&#xD;
               -  True abstinence is 100% of time no sexual intercourse (male's penis enters the&#xD;
                  female's vagina). (Periodic abstinence [e.g. calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods] and withdrawal are not acceptable methods of&#xD;
                  contraception).&#xD;
&#xD;
                  **Acceptable forms of primary contraception include monogamous relationship with&#xD;
                  a vasectomized partner who has been vasectomized for180 days or more prior to the&#xD;
                  subject receiving the influenza challenge virus, intrauterine devices, birth&#xD;
                  control pills, and injectable/implantable/insertable hormonal birth control&#xD;
                  products. Must use at least one acceptable primary form of contraception for at&#xD;
                  least 30 days prior to challenge and at least one acceptable primary form of&#xD;
                  contraception during the remainder of the study or approximately 57 days after&#xD;
                  admission to the confinement unit.&#xD;
&#xD;
             NOTE: These criteria are applicable to female subjects in a heterosexual relationship&#xD;
             AND of child-bearing potential. These criteria do not apply to subjects in a same sex&#xD;
             relationship.&#xD;
&#xD;
          6. Non-habitual smoker* of tobacco, e-cigarettes or marijuana&#xD;
&#xD;
             *Non-habitual smokers are those who smoke no more than four cigarettes, other tobacco&#xD;
             products, e-cigarettes (to include vaping and juuling products) or marijuana in a week&#xD;
             and agree not to smoke cigarettes, other tobacco products, e-cigarettes and/or&#xD;
             marijuana products during participation in the study.&#xD;
&#xD;
          7. No self-reported or known history of alcoholism within the last 2 years and agrees to&#xD;
             abstain from alcohol for at least one week before admission and throughout the&#xD;
             inpatient period&#xD;
&#xD;
          8. No self-reported or known history of restricted drug use* for at least 30 days prior&#xD;
             to challenge and agrees to abstain from restricted drugs for at least one week before&#xD;
             admission and throughout the inpatient period *Including forms of marijuana not&#xD;
             included in criterion #6&#xD;
&#xD;
          9. Negative drug urine toxicology result on screening (i.e., amphetamines, cocaine, and&#xD;
             opiates) and on admission to the challenge unit (i.e., amphetamines, cocaine, opiates,&#xD;
             and cannabinoids)&#xD;
&#xD;
         10. Agree not to use the listed prescription or over-the-counter medications* within 7&#xD;
             days prior to inpatient stay and through inpatient stay, unless approved by the&#xD;
             investigator *Oseltamivir, zanamivir, peramivir, baloxavir marboxil, amantadine&#xD;
             (generic) and rimantadine (Flumadine and generic), aspirin, intranasal steroids,&#xD;
             decongestants, antihistamines, and other non-steroidal anti-inflammatory drugs&#xD;
             (NSAIDs)&#xD;
&#xD;
         11. In good health*, and do not have clinically significant medical, psychiatric, chronic&#xD;
             or intermittent health conditions including those listed in Exclusion Criteria&#xD;
&#xD;
             *Good health, as determined by medical history, medication use and physical&#xD;
             examination to evaluate ongoing chronic medical or psychiatric diagnoses or&#xD;
             conditions, defined as those that have been present for at least 90 days, which would&#xD;
             not affect the assessment of the safety of subjects or the immunogenicity of&#xD;
             challenge. These medical diagnoses or conditions should be stable for the last 90 days&#xD;
             (no hospitalizations, emergency room (ER) or urgent care for condition (excluding&#xD;
             musculoskeletal conditions) and not listed in Exclusion Criteria. Subjects may be on&#xD;
             medications only if the condition or disease is stable and not deteriorating, if the&#xD;
             medical intervention (such as device or medication) was not available during the&#xD;
             maximal inpatient period of time, medications are not listed in the Exclusion Criteria&#xD;
             and pose no additional risk to subject safety or assessment of adverse events. This&#xD;
             also includes no change in prescription medication, dose or frequency as a result of&#xD;
             new symptoms or deterioration of the medical diagnosis or condition in the 90 days&#xD;
             prior to enrollment. Any prescription change that is due to change of health care&#xD;
             provider, insurance company, etc., or that is done for financial reasons, as long as&#xD;
             in the same class of medication, will not be considered a deviation of this inclusion&#xD;
             criterion. Any change in prescription medication due to improvement of a disease&#xD;
             outcome (e.g., lowering of the dosage or frequency), as determined by the site&#xD;
             principal investigator (PI) or designated clinician licensed to make medical diagnoses&#xD;
             and listed on Form FDA 1572, will not be considered a deviation of this inclusion&#xD;
             criterion.&#xD;
&#xD;
         12. Vital signs as follows:&#xD;
&#xD;
               -  Pulse is 47 to 99 beats per minute, inclusive&#xD;
&#xD;
               -  Systolic blood pressure is 85 to 139 mmHg, inclusive&#xD;
&#xD;
               -  Diastolic blood pressure is 55 to 89 mmHg, inclusive&#xD;
&#xD;
               -  Saturation of Peripheral Oxygen (SpO2) &gt;/= 95%; Respiratory Rate (RR) &lt;/= 18&#xD;
&#xD;
               -  Oral temperature is less than 100.6 degrees Fahrenheit&#xD;
&#xD;
         13. Eligibility laboratory values White Blood Cell (WBC), Absolute Lymphocyte Count,&#xD;
             Hemoglobin (Hgb), Platelets (PLTs), Alanine Transaminase (ALT) and Creatinine(Cr) are&#xD;
             within acceptable parameters*&#xD;
&#xD;
             *Labs within normal range or grade 1 abnormalities deemed not clinically significant&#xD;
             by a study investigator are considered acceptable&#xD;
&#xD;
         14. Body mass index (BMI) &gt; 18.5 and &lt; 40 kg/m2 at screening&#xD;
&#xD;
         15. Other screening tests Electrocardiogram (ECG) and Chest x-ray(CXR) are within normal&#xD;
             reference range or not deemed clinically significant by the Principle Investigator(PI)&#xD;
             or appropriate sub-investigator*&#xD;
&#xD;
             *Designated clinician licensed to make medical diagnoses and listed on the Form FDA&#xD;
             1572&#xD;
&#xD;
         16. Negative test for Human Immunodeficiency Virus (HIV), hepatitis B virus (HBV), and&#xD;
             hepatitis C virus (HCV) at screening&#xD;
&#xD;
         17. Negative respiratory virus panel by BIOFIRE(R) FILMARRAY(R) respiratory panel by&#xD;
             bioMÃ©rieux or by Luminex xTAG(R) on Day -2, and Day -1&#xD;
&#xD;
         18. Negative RT-PCR test for severe acute respiratory syndrome coronavirus 2(SARS-CoV 2)&#xD;
             on screening and Day -2&#xD;
&#xD;
         19. Hemagglutination Inhibition Test (HAI) antibody titer &lt;/=1:40 against influenza&#xD;
             A/Texas/71/2017 (H3N2) at screening&#xD;
&#xD;
         20. Receipt of the recommended number of doses of an (Emergency Use Authorization) EUA&#xD;
             authorized or licensed coronavirus disease of 2019 (COVID-19) vaccine product = two&#xD;
             weeks prior to admission to the confinement unit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of self-reported or medically documented significant medical or psychiatric&#xD;
             condition(s)*&#xD;
&#xD;
             *Significant medical or psychiatric conditions include but are not limited to:&#xD;
&#xD;
               1. Respiratory disease (e.g., chronic obstructive pulmonary disease [COPD], asthma)&#xD;
                  requiring daily medications [Inhaled, oral or intravenous (IV) corticosteroids,&#xD;
                  leukotriene modifiers, long and short acting beta agonists, theophylline,&#xD;
                  ipratropium, biologics] or any treatment for respiratory disease exacerbations&#xD;
                  (e.g., asthma exacerbation) within the last 5 years&#xD;
&#xD;
               2. Presence of any febrile illness or symptoms suggestive of a respiratory infection&#xD;
                  within two weeks prior to challenge&#xD;
&#xD;
               3. Significant cardiovascular disease (e.g., congestive heart failure,&#xD;
                  cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis&#xD;
                  as an adult.&#xD;
&#xD;
               4. Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures,&#xD;
                  encephalopathy, focal neurologic deficits, Guillain-Barre syndrome,&#xD;
                  encephalomyelitis or transverse myelitis).&#xD;
&#xD;
               5. Ongoing malignancy or recent diagnosis of malignancy in the last five years&#xD;
                  (excluding basal cell carcinoma of the skin)&#xD;
&#xD;
               6. Presence of an autoimmune disease.&#xD;
&#xD;
               7. Immunodeficiency of any cause.&#xD;
&#xD;
               8. History of diabetes.&#xD;
&#xD;
          2. Presence of immunosuppression or any medications that may be associated with impaired&#xD;
             immune responsiveness*&#xD;
&#xD;
             *Including, but not limited to, corticosteroids exceeding 10 mg/day of prednisone&#xD;
             equivalent, allergy injections, immunoglobulin, interferon, immunomodulators,&#xD;
             cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs during&#xD;
             the preceding 12-month period prior to screening. Low dose topical and intranasal&#xD;
             steroid preparations used for a discrete period of time are permitted.&#xD;
&#xD;
          3. Known allergy or intolerance to treatments for influenza (including any neuraminidase&#xD;
             inhibitors or baloxavir marboxil).&#xD;
&#xD;
          4. Known allergy to two or more classes of antibiotics (e.g., penicillins,&#xD;
             cephalosporins, fluoroquinolones, or glycopeptides).&#xD;
&#xD;
          5. Known allergy to excipients* in the challenge virus inoculum.&#xD;
&#xD;
             *Sucrose, KH2PO4, K2HPO4, L-glutamic acid (in SPG diluent)&#xD;
&#xD;
          6. Receipt or planned receipt of any investigational drug/investigational&#xD;
             vaccine/licensed vaccine, except for a licensed or emergency use authorized&#xD;
             coronavirus disease of 2019 (COVID-19) vaccine product, within 30 days prior to the&#xD;
             date of challenge.&#xD;
&#xD;
          7. Prior enrollment in any influenza virus challenge study within the past 2 years.&#xD;
&#xD;
          8. Currently enrolled in any investigational study or intends to enroll in such a study&#xD;
             within the ensuing study period.*&#xD;
&#xD;
             *Co-enrollment in an observational study, an investigational study in an&#xD;
             follow-up/post-vaccination stage, or a study involving a licensed drug or biologic may&#xD;
             be allowed at the investigator's discretion.&#xD;
&#xD;
          9. Receipt of any influenza vaccine six months prior to challenge or plans to receive&#xD;
             influenza vaccine during the study (approximately 57 days after challenge).&#xD;
&#xD;
         10. History of a previous severe allergic reaction to any drug or biologic with&#xD;
             generalized urticaria, angioedema, or anaphylaxis.&#xD;
&#xD;
         11. Receipt of blood or blood products during the six months prior to the planned date of&#xD;
             challenge.&#xD;
&#xD;
         12. Plans to donate blood or blood products during the study. (approximately 102 days).&#xD;
&#xD;
         13. Any condition (including medical and psychiatric conditions) that, in the opinion of&#xD;
             the Investigator, might interfere with the safety of the subject and/or study&#xD;
             objectives.&#xD;
&#xD;
         14. An ongoing symptomatic condition for which subject has had or has ongoing medical&#xD;
             investigations but has not yet received a diagnosis or treatment plan e.g., ongoing&#xD;
             fatigue without a diagnosis.&#xD;
&#xD;
         15. Known close contact with anyone known to have or suspected to have a respiratory viral&#xD;
             illness within 7 days prior to challenge.&#xD;
&#xD;
         16. Significant abnormality altering anatomy of nose/nasopharynx (including significant&#xD;
             nasal polyps), clinically significant nasal deviation, or nasal/sinus surgery within&#xD;
             180 days prior to challenge.&#xD;
&#xD;
         17. History in the last five years of chronic or frequent intermittent sinusitis.&#xD;
&#xD;
         18. Recent history (180 days) of epistaxis or anatomic or neurologic abnormality impairing&#xD;
             the gag reflex or contributing to aspiration.&#xD;
&#xD;
         19. Currently using an internal cardiac device such as a pacemaker or other implanted&#xD;
             electronic medical devices.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Woods</last_name>
    <phone>19199700351</phone>
    <email>chris.woods@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Maryland School of Medicine - Center for Vaccine Development - Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-4606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Trent Drive</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 12, 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>A/Texas/71/2017</keyword>
  <keyword>Influenza</keyword>
  <keyword>Influenza Challenge Study</keyword>
  <keyword>Recombinant H3N2</keyword>
  <keyword>Recombinant H3N2 Influenza Strain</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

